Cover Image
市場調查報告書

MediPoint:主動脈覆膜支架 - 亞太地區市場分析與預測

MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts

出版商 GlobalData 商品編碼 320353
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:主動脈覆膜支架 - 亞太地區市場分析與預測 MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts
出版日期: 2014年10月31日 內容資訊: 英文 200 Pages
簡介

主動脈覆膜支架一般用於加強稱作動脈瘤的動脈內脆弱的部份。1991年導入以來廣泛接受、利用,不過,可認為這與血管支架的設計進步,能對應各種解剖學特性的設備的多樣性有很大的關係。現在,由於微創和恢復時間快,在破裂動脈瘤的治療中這些設備也大量地受到利用。

本報告提供亞太地區的主動脈覆膜支架市場相關調查、主動脈瘤的治療方法、治療的指南、模式、未滿足需求、主動脈覆膜支架市場的各種影響因素及市場機會分析、企業及企業間的配合措施、主要產品概要、產品開發趨勢、主要企業簡介、市場收益的變化與預測等彙整資料。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 概要
  • 適應症
    • 腹部主動脈血管瘤
    • 胸部主動脈瘤
    • 主動脈剝離
  • 臨床性結果
    • 生活方式的改善
    • 投藥
    • 開放性手術
    • 血管內修復
  • 治療趨勢
    • 血管內主動脈瘤修復
    • 胸部血管內主動脈瘤修復
  • 市場進入
    • 引進
    • 法律規章
    • 償付
  • 法規上的課題/回收
  • 合併、契約、收購等
    • Medtronic,收購Covidien
    • TriVascular,募集1億美元的IPO
    • Lombard Medical,美國募集IPO
    • TriVascular,在E系列籌措4000萬美元
    • 和LifeTech Scientific、Medtronic合作等
  • 經濟影響
    • 動脈瘤的經濟影響
    • 主動脈瘤的治療費

第4章 未滿足需求

  • 併發症的應對
    • 滲漏
    • 缺血性併發症
    • 四肢血栓症
    • 感染疾病
    • 胸部主動脈瘤的下身麻痺
  • 密封區、定位區
  • 短頭
  • 成本控制
  • Low profile系統
  • 客製化開窗型血管支架
  • 分枝血管支架
  • 胸部血管動脈瘤修復的未滿足需求
  • 長期臨床資料

第5章 市場機會分析

  • 新興市場
  • 胸部主動脈疾病市場
  • 追加醫生的訓練計劃
  • 顛覆性技術
  • 微創趨勢

第6章 推動市場要素、障礙、替代

  • 推進因素:盛行率的擴大
    • 真性糖尿病
    • 高血壓
    • 肥胖症
    • 抽煙
  • 推進因素:老化
  • 推進因素:影像
  • 推進因素:血管內療法改善臨床結果
  • 推進因素:時間的節約
  • 推進因素:患者的需求與認識
  • 推進因素:技術發展
    • 客製化的分枝、開窗型血管支架
    • Low profile遞送系統
  • 推進因素:競爭及技術創新的活躍
  • 障礙:風險企業資金的可用性
  • 障礙:法規擴大的負擔
  • 障礙:治療費用高
  • 障礙:長期有效性的證明
  • 障礙:過度撮像增加曝露高輻射劑量
  • 外科規定
  • 障礙:醫療設備物品稅
  • 替代:開放性手術
  • 替代:煙囪技術 vs 開窗型移植

第7章 競爭分析

  • 概要
  • 主要的已上市產品
    • 血管內動脈瘤修復及胸部血管內動脈瘤修復產品

第8章 開發平台的評估

  • 概要
  • 產品簡介
    • Altura Medical Endograft
    • Cordis INCRAFT
    • EndoSpan Horizon
    • EndoSpan Nexus
    • MicroPort Scientific Castor分枝血管支架系統
    • BiFlow Medical的新側面分枝支架
    • Endoluminal Sciences的覆膜支架機制
    • Medtronic Valiant Mona LSA血管支架系統
    • Endologix Ventana的開窗型血管支架

第9章 關注的臨床試驗

  • 概要
  • Altura Medical
  • Cook Medical
  • Gore Medical
  • Terumo Corporation
  • Endologix
  • TriVascular
  • Bolton Medical
  • Medtronic
  • Cordis Corporation

第10章 現在及未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Cook Medical
    • Endologix
    • Gore Medical
    • Medtronic
    • Terumo Corporation
    • Altura Medical
    • Aptus Endosystems
    • Bolton Medical
    • Braile Biomedica
    • B. Braun
    • Cardiatis
    • LeMaitre Vascular
    • Lifetech Scientific
    • Getinge Group
    • Grikin Advanced Materials
    • Johnson & Johnson的Cordis Corporation
    • Jotec
    • Lombard Medical
    • MicroPort Scientific Corporation
    • Nano Endoluminal
    • TriVascular
    • Weike Medical Apparatus and Instrument
    • YTH Biological Material Scitech

第11章 市場展望

  • 各市場區隔
    • 概要
    • 血管內動脈瘤修復
    • 胸部血管內動脈瘤修復
  • 各地區
    • 亞太地區

第12章 附錄

圖表

目錄
Product Code: GDME1120CFR

Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. Since their introduction in patients in 1991, aortic stent graft devices have gained wide acceptance and availability, with their adoption fueled in great part by advances in stent-graft design and by a variety of devices for various anatomic features. Over time, these devices have gained traction for use in patients with ruptured aneurysms because they are minimally invasive and have shorter recovery times.

In this report, GlobalData analyzes the use of stent graft systems for treating patients with AAA and TAA for APAC (Japan, China, and India). Within each segment, the revenue stream from stent graft sales are tracked and estimated based on GlobalData's primary and secondary research.

Scope

  • An overview of Aortic Stent Grafts, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized APAC Aortic Stent Grafts market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Aortic Stent Grafts.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Aortic Stent Grafts sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the APAC Aortic Stent Grafts market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the APAC Aortic Stent Grafts market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the APAC Aortic Stent Grafts market landscape Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Industry Overview

  • 3.1. Overview
  • 3.2. Indications
    • 3.2.1. Aortic Abdominal Aneurysm
    • 3.2.2. Thoracic Aortic Aneurysm
    • 3.2.3. Aortic Dissection
  • 3.3. Clinical Outcomes
    • 3.3.1. Lifestyle Changes
    • 3.3.2. Medication
    • 3.3.3. Open Surgery
    • 3.3.4. Endovascular Repair
  • 3.4. Procedure Trends
    • 3.4.1. Endovascular Aneurysm Repair
    • 3.4.2. Thoracic Endovascular Aneurysm Repair
  • 3.5. Market Access
    • 3.5.1. Adoption
    • 3.5.2. Regulation
    • 3.5.3. Reimbursement
  • 3.6. Regulatory Issues/Recalls
    • 3.6.1. Anaconda Back on the Market in March 2014 after a Voluntary Recall of Anaconda by Vascutek
    • 3.6.2. Terminated FDA's Class II Recall of TriVascular's Ovation Prime in April 2014
  • 3.7. Mergers, Deals, and Acquisitions
    • 3.7.1. Medtronic Acquires Covidien
    • 3.7.2. TriVascular Launches $100m Initial Public Offering
    • 3.7.3. Lombard Medical Pursues US Initial Public Offering
    • 3.7.4. TriVascular Raises $40m in Series E Financing
    • 3.7.5. LifeTech Scientific Creates Partnership with Medtronic
    • 3.7.6. LeMaitre Vascular Terminates Distribution Agreement with Endologix
    • 3.7.7. Jotec Enters Licensing Agreement with Hydromer
    • 3.7.8. Endologix Public Offering of Notes
    • 3.7.9. Aptus Endosystems Secures Financing
    • 3.7.10. Altura Medical Secures Financing
    • 3.7.11. Endologix Acquires Nellix Endovascular
  • 3.8. Economic Impact
    • 3.8.1. Economic Impact of Aneurysms
    • 3.8.2. Treatment Costs of Aortic Aneurysms

4. Unmet Needs

  • 4.1. Addressing the Complications
    • 4.1.1. Endoleaks
    • 4.1.2. Ischemic Complications
    • 4.1.3. Limb Thrombosis
    • 4.1.4. Infection
    • 4.1.5. Paraplegia in Thoracic Aortic Aneurysm
  • 4.2. The Seal and Landing Zone
  • 4.3. Short Neck
  • 4.4. Cost Containment
  • 4.5. More Low Profile Systems
  • 4.6. Customized Fenestrated Stent Grafts
  • 4.7. Multi-Branch Stent Grafts
  • 4.8. Thoracic Endovascular Aneurysm Repair Unmet Needs
  • 4.9. Long-Term Clinical Data

5. Market Opportunity Analysis

  • 5.1. Emerging Markets
  • 5.2. Thoracic Aortic Disease Market
  • 5.3. Addition of Physician Training Programs
  • 5.4. Disruptive Technologies
  • 5.5. Minimally Invasive Trend

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Driver: Rising Disease Prevalence
    • 6.1.1. Diabetes Mellitus
    • 6.1.2. Hypertension
    • 6.1.3. Obesity
    • 6.1.4. Tobacco Use
  • 6.2. Driver: Aging
  • 6.3. Driver: Imaging
  • 6.4. Driver: Improved Clinical Outcomes with Endovascular Therapy
  • 6.5. Driver: Time Savings
  • 6.6. Driver: Patient Demand and Awareness
  • 6.7. Driver: Technological Developments
    • 6.7.1. Custom Branched and Fenestrated Stent Grafts
    • 6.7.2. Low Profile Delivery Systems
  • 6.8. Driver: Rising Competition and Innovation
  • 6.9. Barrier: Availability of Venture Capital
  • 6.10. Barrier: Burden of Rising Regulation
  • 6.11. Barrier: High Treatment Cost
  • 6.12. Barrier: Proving Long-Term Efficacy
  • 6.13. Barrier: High Radiation Dosages with Excessive Imaging
  • 6.14. Surgical Limitations
  • 6.15. Barrier: Medical Device Excise Tax
  • 6.16. Substitute: Open Surgery
  • 6.17. Substitute: Chimney Technique versus Fenestrated Grafts

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Key Marketed Products
    • 7.2.1. Endovascular Aneurysm Repair and Thoracic Endovascular Aneurysm Repair Products

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Product Profiles
    • 8.2.1. Altura Medical Endograft
    • 8.2.2. Cordis INCRAFT
    • 8.2.3. EndoSpan Horizon
    • 8.2.4. EndoSpan Nexus
    • 8.2.5. MicroPort Scientific Castor Branched Stent Graft System
    • 8.2.6. BiFlow Medical Novel Side-Branch Stent
    • 8.2.7. Endoluminal Sciences Endograft Mechanism
    • 8.2.8. Medtronic Valiant Mona LSA Stent Graft System
    • 8.2.9. Endologix Ventana Fenestrated Stent Graft

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Altura Medical
  • 9.3. Cook Medical
  • 9.4. Gore Medical
  • 9.5. Terumo Corporation
  • 9.6. Endologix
  • 9.7. TriVascular
  • 9.8. Bolton Medical
  • 9.9. Medtronic
  • 9.10. Cordis Corporation

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Cook Medical
    • 10.3.2. Endologix
    • 10.3.3. Gore Medical
    • 10.3.4. Medtronic
    • 10.3.5. Terumo Corporation
    • 10.3.6. Altura Medical
    • 10.3.7. Aptus Endosystems
    • 10.3.8. Bolton Medical
    • 10.3.9. Braile Biomedica
    • 10.3.10. B. Braun
    • 10.3.11. Cardiatis
    • 10.3.12. LeMaitre Vascular
    • 10.3.13. Lifetech Scientific
    • 10.3.14. Getinge Group
    • 10.3.15. Grikin Advanced Materials
    • 10.3.16. Johnson & Johnson's Cordis Corporation
    • 10.3.17. Jotec
    • 10.3.18. Lombard Medical
    • 10.3.19. MicroPort Scientific Corporation
    • 10.3.20. Nano Endoluminal
    • 10.3.21. TriVascular
    • 10.3.22. Weike Medical Apparatus and Instrument
    • 10.3.23. YTH Biological Material Scitech

11. Market Outlook

  • 11.1. By Market Segment
    • 11.1.1. Overview
    • 11.1.2. Endovascular Aneurysm Repair
    • 11.1.3. Thoracic Endovascular Aneurysm Repair
  • 11.2. By Geography
    • 11.2.1. APAC Overview

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Research Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in this Study
    • 12.4.1. Christopher Abularrage, MD, FACS
    • 12.4.2. Gaspar Mestres Alomar, MD
    • 12.4.3. Enio Buffolo, MD, PhD
    • 12.4.4. Ludovic Canaud, MD, PhD
    • 12.4.5. Holger Eggebrecht, MD
    • 12.4.6. Daisuke Fukui, MD, PhD
    • 12.4.7. Germano Melissano, MD
    • 12.4.8. Dr. Raghuram Sekhar MS, FRCS (Edinburgh), FRCS (Glasgow)
    • 12.4.9. Ferdinand Serracino-Inglott, MD, MSc, FRCSI, FRCS (Gen Surg), DIC
    • 12.4.10. Jiang Xiong, MD, PhD
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research - Physician and Industry Interviews
    • 12.5.3. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: Summary of Indications, Symptoms, and Treatments
  • Table 2: Thoracic Aortic Aneurysm Types
  • Table 3: Medications for Reducing Risk of Aneurysm Growth and Rupture
  • Table 4: Advantages and Disadvantages of Open Repair versus Endovascular Repair
  • Table 5: Direct and Indirect Costs of Open Surgery and Endovascular Repair
  • Table 6: Comparison Costs and Other Variables for Treating AAA By Open Repair and Stent Grafts in 2012 ($US)
  • Table 7: Endoleak Types
  • Table 8: Zenith Family Marketed Products
  • Table 9: Zenith AAA SWOT
  • Table 10: Zenith TAA SWOT
  • Table 11: Endologix's Marketed Products
  • Table 12: AFX Endovascular SWOT
  • Table 13: IntuiTrak Powerlink System SWOT
  • Table 14: Gore Medical's Marketed Products
  • Table 15: Gore AAA Product SWOT
  • Table 16: Gore TAA Product SWOT
  • Table 17: Medtronic's Marketed Products
  • Table 18: Medtronic AAA Product SWOT
  • Table 19: Medtronic TAA Product SWOT
  • Table 20: Terumo Corporation Marketed Products
  • Table 21: Terumo Corporation AAA Product SWOT
  • Table 22: SWOT Analysis - Altura Medical Endograft
  • Table 23: SWOT Analysis - Cordis INCRAFT
  • Table 24: SWOT Analysis - EndoSpan Horizon
  • Table 25: SWOT Analysis - EndoSpan Nexus
  • Table 26: SWOT Analysis - MicroPort Scientific Castor Branched Stent Graft System
  • Table 27: SWOT Analysis - BiFlow Medical Novel Side-Branch Stent
  • Table 28: SWOT Analysis - Endoluminal Sciences Endograft Mechanism
  • Table 29: SWOT Analysis - Medtronic Valiant Mona LSA Stent Graft
  • Table 30: SWOT Analysis - Endologix Ventana Fenestrated Stent Graft
  • Table 31: Major Clinical Trials of Altura Medical's Aortic Stent Grafts
  • Table 32: Major Clinical Trials of Cook Medical's Aortic Stent Grafts
  • Table 33: Major Clinical Trials of Gore Medical's Aortic Stent Grafts
  • Table 34: Major Clinical Trials of Terumo's Aortic Stent Grafts
  • Table 35: Major Clinical Trials of Endologix's Aortic Stent Grafts
  • Table 36: Major Clinical Trials of TriVascular's Aortic Stent Grafts
  • Table 37: Major Clinical Trials of Bolton Medical's Aortic Stent Grafts
  • Table 38: Major Clinical Trials of Medtronic's Aortic Stent Grafts
  • Table 39: Major Clinical Trials of Cordis' Aortic Stent Grafts
  • Table 40: Company Profile - Cook Medical
  • Table 41: Cook Medical Marketed Products
  • Table 42: SWOT Analysis - Cook Medical
  • Table 43: Company Profile - Endologix Inc.
  • Table 44: Endologix Marketed Products
  • Table 45: Endologix Pipeline Products
  • Table 46: SWOT Analysis - Endologix Inc.
  • Table 47: Company Profile - Gore Medical
  • Table 48: Gore Medical Marketed Products
  • Table 49: SWOT Analysis - Gore Medical
  • Table 50: Company Profile - Medtronic
  • Table 51: Medtronic Marketed Products
  • Table 52: SWOT Analysis - Medtronic
  • Table 53: Company Profile - Terumo Corporation
  • Table 54:Terumo Corporation Marketed Products
  • Table 55: SWOT Analysis - Terumo Corporation
  • Table 56: Company Profile - Altura Medical Inc.
  • Table 57: Altura Medical Inc. Marketed Products
  • Table 58: SWOT Analysis - Altura Medical Inc.
  • Table 59: Company Profile - Aptus Endosystems, Inc.
  • Table 60: Aptus Endosystems Inc. Marketed Products
  • Table 61: SWOT Analysis - Aptus Endosystems Inc.
  • Table 62: Company Profile - Bolton Medical
  • Table 63: Bolton Medical Marketed Products
  • Table 64: SWOT Analysis - Bolton Medical
  • Table 65: Company Profile - Braile Biomedica
  • Table 66: Braile Biomedica Marketed Products
  • Table 67: SWOT Analysis - Braile Biomedica
  • Table 68: Company Profile - B. Braun
  • Table 69: B. Braun Marketed Products
  • Table 70: SWOT Analysis - B. Braun
  • Table 71: Company Profile - Cardiatis
  • Table 72: Cardiatis Marketed Products
  • Table 73: SWOT Analysis - Cardiatis
  • Table 74: Company Profile - LeMaitre Vascular
  • Table 75: LeMaitre Vascular Medical Marketed Products
  • Table 76: SWOT Analysis - LeMaitre Vascular
  • Table 77: Company Profile - Lifetech Scientific
  • Table 78: Lifetech Scientific Marketed Products
  • Table 79: SWOT Analysis - Lifetech Scientific
  • Table 80: Company Profile - Getinge Group
  • Table 81: Getinge Group Marketed Products
  • Table 82: SWOT Analysis - Getinge Group
  • Table 83: Company Profile - Grikin Advanced Materials
  • Table 84: Grikin Advanced Materials Marketed Products
  • Table 85: SWOT Analysis - Grikin Advanced Materials
  • Table 86: Company Profile - Johnson & Johnson Cordis Corporation
  • Table 87: Cordis Corporation's Pipeline Product
  • Table 88: SWOT Analysis - Cordis Corporation
  • Table 89: Company Profile - Jotec
  • Table 90: Jotec's Marketed Products
  • Table 91: SWOT Analysis - Jotec
  • Table 92: Company Profile - Lombard Medical
  • Table 93: Lombard Medical Marketed Products
  • Table 94: SWOT Analysis - Lombard Medical
  • Table 95: Company Profile - Microport Scientific Corporation
  • Table 96: MicroPort Scientific Marketed Products
  • Table 97: SWOT Analysis - MicroPort Scientific
  • Table 98: Company Profile - Nano Endoluminal
  • Table 99: Nano Endoluminal Medical Marketed Products
  • Table 100: SWOT Analysis - Nano Endoluminal
  • Table 101: Company Profile - TriVascular
  • Table 102: TriVascular Marketed Products
  • Table 103: SWOT Analysis - TriVascular
  • Table 104: APAC Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011-2020
  • Table 105: APAC Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Table 106: APAC Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Table 107: Aortic Stent Grafts Sales ($m) Forecast for the APAC Region, 2011-2020
  • Table 108: Aortic Stent Grafts Sales ($m) Forecast for Japan, 2011-2020
  • Table 109: Aortic Stent Grafts Sales ($m) Forecast for China, 2011-2020
  • Table 110: Aortic Stent Grafts Sales ($m) Forecast for India, 2011-2020

List of Figures

  • Figure 1: Treatment Methodology Markov Model
  • Figure 2: Aortic Stent Graft Product Image
  • Figure 3: APAC Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 4: APAC Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 5: APAC Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011-2020
  • Figure 6: APAC Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Figure 7: APAC Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Figure 8: APAC Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 9: Japan Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 10: China Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 11: India Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 12: Aortic Stent Graft Primary Research, Supply and Demand-Side Interviews
Back to Top